Vaxil Bio Stock Profit Margin
| VXL Stock | CAD 0.01 0.00 0.00% |
Vaxil Bio fundamentals help investors to digest information that contributes to Vaxil Bio's financial success or failures. It also enables traders to predict the movement of Vaxil Stock. The fundamental analysis module provides a way to measure Vaxil Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vaxil Bio stock.
| Last Reported | Projected for Next Year |
Vaxil | Profit Margin |
Vaxil Bio Company Profit Margin Analysis
Vaxil Bio's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Vaxil Profit Margin Driver Correlations
Understanding the fundamental principles of building solid financial models for Vaxil Bio is extremely important. It helps to project a fair market value of Vaxil Stock properly, considering its historical fundamentals such as Profit Margin. Since Vaxil Bio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Vaxil Bio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Vaxil Bio's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, Vaxil Bio has a Profit Margin of 0.0%. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The profit margin for all Canada stocks is 100.0% lower than that of the firm.
Vaxil Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vaxil Bio's direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vaxil Bio could also be used in its relative valuation, which is a method of valuing Vaxil Bio by comparing valuation metrics of similar companies.Vaxil Bio is currently under evaluation in profit margin category among its peers.
Vaxil Bio Current Valuation Drivers
We derive many important indicators used in calculating different scores of Vaxil Bio from analyzing Vaxil Bio's financial statements. These drivers represent accounts that assess Vaxil Bio's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Vaxil Bio's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 3.1M | 30.5M | 10.2M | 2.7M | 2.5M | 3.5M | |
| Enterprise Value | 3.0M | 29.0M | 8.0M | 1.2M | 1.1M | 1.1M |
Vaxil Fundamentals
| Return On Equity | -0.2 | ||||
| Return On Asset | -0.1 | ||||
| Current Valuation | 449.79 K | ||||
| Shares Outstanding | 136.98 M | ||||
| Shares Owned By Insiders | 8.16 % | ||||
| Shares Owned By Institutions | 0.01 % | ||||
| Number Of Shares Shorted | 3.73 K | ||||
| Price To Earning | (1.40) X | ||||
| Price To Book | 2.39 X | ||||
| EBITDA | (252) | ||||
| Net Income | (254 K) | ||||
| Cash And Equivalents | 307 K | ||||
| Total Debt | 85 K | ||||
| Debt To Equity | 11.20 % | ||||
| Current Ratio | 1.07 X | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (561 K) | ||||
| Short Ratio | 1.77 X | ||||
| Beta | -3.67 | ||||
| Market Capitalization | 1.37 M | ||||
| Total Asset | 976 K | ||||
| Retained Earnings | (19.36 M) | ||||
| Working Capital | 891 K | ||||
| Net Asset | 976 K |
About Vaxil Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vaxil Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vaxil Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vaxil Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Vaxil Stock Analysis
When running Vaxil Bio's price analysis, check to measure Vaxil Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxil Bio is operating at the current time. Most of Vaxil Bio's value examination focuses on studying past and present price action to predict the probability of Vaxil Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxil Bio's price. Additionally, you may evaluate how the addition of Vaxil Bio to your portfolios can decrease your overall portfolio volatility.